Reference number(s)
876-A, 215-A

Initial Prior Authorization Strattera

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Strattera	atomoxetine HCl

Indications

FDA-approved Indications

Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).

The efficacy of Strattera Capsules was established in seven clinical trials in outpatients with ADHD: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trials in adults, and one maintenance trial in pediatrics (ages 6 to 15).

Coverage Criteria

Attention-Deficit/Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD)

Authorization may be granted when the patient has a diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD) when ALL of the following criteria are met:

- The diagnosis has been appropriately documented (e.g., evaluated by a complete clinical assessment, using DSM-5, standardized rating scales, interviews/questionnaires)
- The patient will be monitored closely for suicidal thinking or behavior, clinical worsening, and unusual changes in behavior

Continuation of Therapy

Attention-Deficit/Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD)

Authorization may be granted when the patient has a diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD) when ALL of the following criteria are met:

- The patient has achieved or maintained improvement in their signs and symptoms of ADHD/ADD from baseline
- The patient's need for continued therapy has been assessed within the previous year
- The patient will continue to be monitored closely for suicidal thinking or behavior, clinical worsening, and unusual changes in behavior

Duration of Approval (DOA)

- 876-A: DOA: 36 months
- 215-A: DOA: 12 months

References

1. Strattera [package insert]. Indianapolis, IN: Lilly USA, LLC; January 2022.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed November 6, 2024.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 11/6/2024).
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision. Arlington, Virginia: American Psychiatric Association; 2022.
5. Wolraich ML, Hagan JF, Allan C, et al. AAP Subcommittee On Children And Adolescents With Attention-Deficit/Hyperactive Disorder. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528.

Reference number(s)
876-A, 215-A

Document History

Written by: UM Development (JG)

Date Written: 12/2002

Revised: (MG) 01/2004; (TM) 12/2004; (NB) 11/2005; (CT) 02/2006; (AM) 02/2007, 11/2007, 11/2008; (MS) 09/2009, 11/2010; (CY) 11/2011; (PL) 10/2012 (created MDC-2 due to extended commercial duration); (CY) 11/2012; (MS) 11/2013, 04/2014 (align with 1 sheet); (RP) 11/2014; (MS) 11/2015, (SE) 06/2016 (created separate Med D); (RP) 11/2016, 11/2017 (no clinical changes; combined ref#s), 11/2018 (no clinical changes), 11/2019 (removed MDC designation; no clinical changes); (PM) 11/2020 (no clinical changes), 11/2021(no clinical changes); (ASA) 11/2022 (added COT criteria and added criteria for prescriber to confirm diagnosis by appropriate tests and evaluations), 11/2023 (no clinical changes); (MRS) 11/2024 (no clinical changes)

Reviewed: CRC 12/2002; 01/2004; Medical Affairs (MM) 12/2004, 06/2005, 02/2006; (WF) 02/2007, 1/2008, 11/2008, 09/2009; (KP) 11/2010, 11/2011; (DC) 11/2012; (LB) 11/2013; (DNC) 11/2014; (GD) 11/2015; (ME) 11/2016; (CHART) 11/27/2019; (CHART) 12/3/2020, 12/2/2021, 12/01/2022, 11/30/2023, 11/21/2024

External Review: 02/2003, 02/2004, 05/2005, 06/2006, 06/2007, 04/2008, 02/2009, 02/2010, 02/2011, 02/2012, 02/2013, 02/2014, 02/2015, 02/2016, 02/2017, 02/2018, 02/2019, 02/2020; 02/2021, 02/2022, 02/2023, 02/2024, 02/2025

CRITERIA FOR APPROVAL

1	Does the patient have a diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD)? [If Yes, then go to 2. If No, then no further questions.]	Yes	No
2	Is this request for continuation of therapy? [If Yes, then go to 3. If No, then go to 6.]	Yes	No
3	Has the patient achieved or maintained improvement in their signs and symptoms of ADHD/ADD (Attention-Deficit/Hyperactivity Disorder or Attention Deficit Disorder) from baseline? [If Yes, then go to 4. If No, then no further questions.]	Yes	No
4	Has the patient's need for continued therapy been assessed within the previous year? [If Yes, then go to 5. If No, then no further questions.]	Yes	No
5	Will the patient continue to be monitored closely for suicidal thinking or behavior, clinical worsening, and unusual changes in behavior? [No further questions]	Yes	No

6	Has the diagnosis been appropriately documented (e.g., evaluated by a complete clinical assessment, using DSM-5, standardized rating scales, interviews/questionnaires)? [If Yes, then go to 7. If No, then no further questions.]	Yes	No
7	Will the patient be monitored closely for suicidal thinking or behavior, clinical worsening, and unusual changes in behavior? [No further questions]	Yes	No

Mapping Instructions			
	Yes	**No**	**DENIAL REASONS**
1.	Go to 2	Deny	Your plan only covers this drug when it is used for certain health conditions. Covered uses are Attention-Deficit/Hyperactivity Disorder (ADHD) and Attention Deficit Disorder (ADD). Your plan does not cover this drug for your health condition that your doctor told us you have. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review. [Short Description: Diagnosis]
2.	Go to 3	Go to 6	
3.	Go to 4	Deny	Your plan only covers this drug if it works well for you. We have denied your request because the drug did not work well for you. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review. [Short Description: Continuation - Efficacy]

4.	Go to 5	Deny	Your plan only covers this drug when your doctor has reviewed your therapy within the last year and you still have a need for it. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review. [Short Description: Continuation - Reassessment]
5.	Approve, 36 Months	Deny	Your plan only covers this drug when your doctor will watch for unusual changes in your mood. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review. [Short Description: Monitoring for Behavioral Changes]
6.	Go to 7	Deny	Your plan only covers this drug when you have an assessment that shows you have Attention-Deficit/Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD). We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review. [Short Description: Positive assessment]
7.	Approve, 36 Months	Deny	Your plan only covers this drug when your doctor will watch for unusual changes in your mood. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.

			[Short Description: Monitoring for Behavioral Changes]